NirvaMed

NirvaMed Inc. is a pioneering medical device startup developing advanced therapies to protect heart muscle and improve patient outcomes. Its proprietary heart-cooling technology delivers rapid, localized cooling directly to the myocardium—lowering heart temperature within two minutes. This targeted approach is designed to significantly reduce cardiac damage during ST-Elevation Myocardial Infarction (STEMI), a condition responsible for one in every seven deaths in the U.S. and long-term disability in one-third

NirvaMed’s business strategy now addresses both STEMI and complex percutaneous coronary intervention (PCI) procedures—two critical and underserved segments in interventional cardiology. The company holds four granted patents in the U.S. and has filed seven additional applications across the U.S. and Europe. Headquartered in Minnesota, NirvaMed also maintains an industrial fellowship with Siriraj Hospital of Mahidol University in Bangkok, Thailand, to accelerate clinical development, product design, and reimbursement planning across international markets.